Biography

Dr. Wenjuan Nie, Chief Physician at Beijing Chest Hospital, specializes in tuberculosis (TB) diagnosis, treatment, and nosocomial infection control. With an M.Sc. in Internal Medicine (Beijing Tuberculosis & Thoracic Tumor Institute), she leads research on TB biomarkers, antimicrobial efficacy, and drug safety. Recent first/corresponding-authored publications in Cytokine, Biomedical and Environmental Sciences, and Antimicrobial Resistance & Infection Control explore TB bacterial load monitoring, moxifloxacin efficacy, and hospital transmission dynamics. She has co-developed national guidelines for cycloserine/clofazimine use in TB and participated in multicenter trials on drug-induced liver injury. Her work bridges clinical practice with translational TB research.

Expertise

TB Diagnostics
Public Health

Key Impacts

Early efficacy and preliminary safety of a novel 6-month regimen containing contezolid, delamanid, bedaquiline (CODA) and fluoroquinolones for Chinese rifampin-resistant people with TB

This first real-world evaluation of 6-month CZD-containing regimens in China demonstrates non-inferior early efficacy versus standard therapy with markedly improved neurological/hematological safety. CZD emerges as a viable LZD alternative for RR-TB optimization, though 24-month follow-up will confirm sustained outcomes.ClinicalTrials Identifier: NCT06081361

Source: Conference 2024